Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis

Chihiro Shimazaki, Shin ichi Fuchida, Kenshi Suzuki, Tadao Ishida, Hirokazu Imai, Morio Sawamura, Hiroyuki Takamatsu, Masahiro Abe, Toshihiro Miyamoto, Hiroyuki Hata, Masahito Yamada, Yukio Ando

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Abstract: We performed a phase 1 study to evaluate the safety and feasibility of bortezomib (BOR) with melphalan and dexamethasone (BMD) in patients with light chain amyloidosis (AL) without severe cardiac failure. Patients received BOR on a twice-weekly schedule (days 1, 4, 8, and 11 of 28-day treatment cycles) at planned doses of 1.0 (dose level 1) and 1.3 (dose level 2) mg/m2 in combination with melphalan 8 mg/m2 on days 1–4 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Dose-limiting toxicity (DLT) was evaluated at the end of cycle one, and treatment was continued for four cycles. Six patients were enrolled at dose level 1, and one showed DLT (grade 3: herpes zoster). Further 3 patients were enrolled at dose level 2, and none experienced DLT. Thus, the maximum tolerated dose was defined as BOR doses of 1.3 mg/m2 for the twice-weekly schedule. A total of 32 cycles of BMD therapy were given, and the most common hematologic toxicity was thrombocytopenia (47 %). Peripheral neuropathy was the most common non-hematologic toxicity (16 %). We demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage. Clinical trial registration: UMIN000006604.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalInternational journal of hematology
Volume103
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Melphalan
Amyloidosis
Dexamethasone
Appointments and Schedules
Maximum Tolerated Dose
Herpes Zoster
Peripheral Nervous System Diseases
Thrombocytopenia
Therapeutics
Heart Failure
Bortezomib
Clinical Trials
Safety
Light

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. / Shimazaki, Chihiro; Fuchida, Shin ichi; Suzuki, Kenshi; Ishida, Tadao; Imai, Hirokazu; Sawamura, Morio; Takamatsu, Hiroyuki; Abe, Masahiro; Miyamoto, Toshihiro; Hata, Hiroyuki; Yamada, Masahito; Ando, Yukio.

In: International journal of hematology, Vol. 103, No. 1, 01.01.2016, p. 79-85.

Research output: Contribution to journalArticle

Shimazaki, C, Fuchida, SI, Suzuki, K, Ishida, T, Imai, H, Sawamura, M, Takamatsu, H, Abe, M, Miyamoto, T, Hata, H, Yamada, M & Ando, Y 2016, 'Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis', International journal of hematology, vol. 103, no. 1, pp. 79-85. https://doi.org/10.1007/s12185-015-1901-2
Shimazaki, Chihiro ; Fuchida, Shin ichi ; Suzuki, Kenshi ; Ishida, Tadao ; Imai, Hirokazu ; Sawamura, Morio ; Takamatsu, Hiroyuki ; Abe, Masahiro ; Miyamoto, Toshihiro ; Hata, Hiroyuki ; Yamada, Masahito ; Ando, Yukio. / Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. In: International journal of hematology. 2016 ; Vol. 103, No. 1. pp. 79-85.
@article{82771a3f67584191af74bd489ec23d96,
title = "Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis",
abstract = "Abstract: We performed a phase 1 study to evaluate the safety and feasibility of bortezomib (BOR) with melphalan and dexamethasone (BMD) in patients with light chain amyloidosis (AL) without severe cardiac failure. Patients received BOR on a twice-weekly schedule (days 1, 4, 8, and 11 of 28-day treatment cycles) at planned doses of 1.0 (dose level 1) and 1.3 (dose level 2) mg/m2 in combination with melphalan 8 mg/m2 on days 1–4 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Dose-limiting toxicity (DLT) was evaluated at the end of cycle one, and treatment was continued for four cycles. Six patients were enrolled at dose level 1, and one showed DLT (grade 3: herpes zoster). Further 3 patients were enrolled at dose level 2, and none experienced DLT. Thus, the maximum tolerated dose was defined as BOR doses of 1.3 mg/m2 for the twice-weekly schedule. A total of 32 cycles of BMD therapy were given, and the most common hematologic toxicity was thrombocytopenia (47 {\%}). Peripheral neuropathy was the most common non-hematologic toxicity (16 {\%}). We demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage. Clinical trial registration: UMIN000006604.",
author = "Chihiro Shimazaki and Fuchida, {Shin ichi} and Kenshi Suzuki and Tadao Ishida and Hirokazu Imai and Morio Sawamura and Hiroyuki Takamatsu and Masahiro Abe and Toshihiro Miyamoto and Hiroyuki Hata and Masahito Yamada and Yukio Ando",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s12185-015-1901-2",
language = "English",
volume = "103",
pages = "79--85",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis

AU - Shimazaki, Chihiro

AU - Fuchida, Shin ichi

AU - Suzuki, Kenshi

AU - Ishida, Tadao

AU - Imai, Hirokazu

AU - Sawamura, Morio

AU - Takamatsu, Hiroyuki

AU - Abe, Masahiro

AU - Miyamoto, Toshihiro

AU - Hata, Hiroyuki

AU - Yamada, Masahito

AU - Ando, Yukio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Abstract: We performed a phase 1 study to evaluate the safety and feasibility of bortezomib (BOR) with melphalan and dexamethasone (BMD) in patients with light chain amyloidosis (AL) without severe cardiac failure. Patients received BOR on a twice-weekly schedule (days 1, 4, 8, and 11 of 28-day treatment cycles) at planned doses of 1.0 (dose level 1) and 1.3 (dose level 2) mg/m2 in combination with melphalan 8 mg/m2 on days 1–4 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Dose-limiting toxicity (DLT) was evaluated at the end of cycle one, and treatment was continued for four cycles. Six patients were enrolled at dose level 1, and one showed DLT (grade 3: herpes zoster). Further 3 patients were enrolled at dose level 2, and none experienced DLT. Thus, the maximum tolerated dose was defined as BOR doses of 1.3 mg/m2 for the twice-weekly schedule. A total of 32 cycles of BMD therapy were given, and the most common hematologic toxicity was thrombocytopenia (47 %). Peripheral neuropathy was the most common non-hematologic toxicity (16 %). We demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage. Clinical trial registration: UMIN000006604.

AB - Abstract: We performed a phase 1 study to evaluate the safety and feasibility of bortezomib (BOR) with melphalan and dexamethasone (BMD) in patients with light chain amyloidosis (AL) without severe cardiac failure. Patients received BOR on a twice-weekly schedule (days 1, 4, 8, and 11 of 28-day treatment cycles) at planned doses of 1.0 (dose level 1) and 1.3 (dose level 2) mg/m2 in combination with melphalan 8 mg/m2 on days 1–4 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Dose-limiting toxicity (DLT) was evaluated at the end of cycle one, and treatment was continued for four cycles. Six patients were enrolled at dose level 1, and one showed DLT (grade 3: herpes zoster). Further 3 patients were enrolled at dose level 2, and none experienced DLT. Thus, the maximum tolerated dose was defined as BOR doses of 1.3 mg/m2 for the twice-weekly schedule. A total of 32 cycles of BMD therapy were given, and the most common hematologic toxicity was thrombocytopenia (47 %). Peripheral neuropathy was the most common non-hematologic toxicity (16 %). We demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage. Clinical trial registration: UMIN000006604.

UR - http://www.scopus.com/inward/record.url?scp=84954379138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954379138&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1901-2

DO - 10.1007/s12185-015-1901-2

M3 - Article

C2 - 26588925

AN - SCOPUS:84954379138

VL - 103

SP - 79

EP - 85

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -